AU2001295721A1 - Vaccine - Google Patents
VaccineInfo
- Publication number
- AU2001295721A1 AU2001295721A1 AU2001295721A AU9572101A AU2001295721A1 AU 2001295721 A1 AU2001295721 A1 AU 2001295721A1 AU 2001295721 A AU2001295721 A AU 2001295721A AU 9572101 A AU9572101 A AU 9572101A AU 2001295721 A1 AU2001295721 A1 AU 2001295721A1
- Authority
- AU
- Australia
- Prior art keywords
- antigen
- vaccine
- inducing
- adjuvant
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229960005486 vaccine Drugs 0.000 title claims description 76
- 108091007433 antigens Proteins 0.000 claims description 102
- 102000036639 antigens Human genes 0.000 claims description 102
- 239000000427 antigen Substances 0.000 claims description 101
- 230000001939 inductive effect Effects 0.000 claims description 72
- 102000004388 Interleukin-4 Human genes 0.000 claims description 59
- 108090000978 Interleukin-4 Proteins 0.000 claims description 59
- 239000002671 adjuvant Substances 0.000 claims description 55
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 34
- 201000008827 tuberculosis Diseases 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 241000187644 Mycobacterium vaccae Species 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 108010065805 Interleukin-12 Proteins 0.000 claims description 9
- 102000013462 Interleukin-12 Human genes 0.000 claims description 9
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 5
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 5
- 229940028885 interleukin-4 Drugs 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 43
- 230000004044 response Effects 0.000 description 43
- 108020004999 messenger RNA Proteins 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 210000004698 lymphocyte Anatomy 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 210000005087 mononuclear cell Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 102000003816 Interleukin-13 Human genes 0.000 description 8
- 108090000176 Interleukin-13 Proteins 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 5
- 229940045513 CTLA4 antagonist Drugs 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 241001274613 Corvus frugilegus Species 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007922 nasal spray Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 2
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- KQHXBDOEECKORE-UHFFFAOYSA-L beryllium sulfate Chemical compound [Be+2].[O-]S([O-])(=O)=O KQHXBDOEECKORE-UHFFFAOYSA-L 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000243777 Trichinella spiralis Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- -1 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000001236 detergent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000018711 interleukin-13 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- HEHQDWUWJVPREQ-XQJZMFRCSA-N lipid X Chemical compound CCCCCCCCCCC[C@@H](O)CC(=O)N[C@H]1[C@@H](OP(O)(O)=O)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)C[C@H](O)CCCCCCCCCCC HEHQDWUWJVPREQ-XQJZMFRCSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229940096911 trichinella spiralis Drugs 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
Vaccine
FIELD OF THE INVENTION
The present invention relates to vaccines against mycobacterial disease, and to the identification of antigen(s) useful in such vaccines.
BACKGROUND TO THE INVENTION
Immunity to tuberculosis is mediated by T-helper 1 (Thl) lymphocytes which recognise antigens from M. tuberculosis and secrete cytokines including interleukin 2 (IL-2) and Interferon gamma (IFNγ). These cells activate macrophages and enhance formation of cytotoxic T cells which are the effector systems that lead to killing of the mycobacteria (Orme et ah, 1993; Orme et al, 1993; Silver et al, 1998; Stenger et ah, 1998).
Prior art attempts to identify antigen(s) from M. tuberculosis that are suitable for use in vaccines rely on the selection criterion of the antigen(s) being able to evoke strong Thl responses.
According to the prior art, lymphocytes from patients, immune individuals or immunised animals are cultured with fractionated or cloned antigens, and evidence of activation of Thl cells is sought as an indication of their suitability for use as antigen(s) in a vaccine.
This evidence is usually sought by looking for production of IFNγ (for example (Lindblad et /., 1997))
There is clearly a need to identify antigens suitable for use in vaccines against M. tuberculosis. The prior art focusses on the the ability to evoke a Thl response as an indicator of suitablility for use in vaccines.
SUMMARY OF THE INVENTION
The present invention is based on the surprising finding that progressive tuberculosis is attributable to the ability of M. tuberculosis to induce not only the dominant Thl response, but also a small response mediated by Th2 lymphocytes (including secretion of IL-4, IL-13) which, when superimposed upon the Thl response, causes imrmmopathology, and impairs the bactericidal functions of the Thl effector mechanisms.
The methods and vaccines of the present invention utilise this surprising finding. It enables the selection of antigens for incorporation into a vaccine by identifying those that tend to evoke a Th2 response. These are the antigens which are causing the immune response to malfunction.
According to the present invention, these antigens are identified and used in vaccine(s) in such a way as to pre-empt inducion of a Th2 response when a subject subsequently meets them in/on M. tuberculosis.
Thus, the present invention relates to methods for identifying Th2-inducing antigens. The present invention further relates to vaccine formulations containing these Th2- inducing antigens.
DETAILED ASPECTS OF THE PRESENT INVENTION
In one aspect, the present invention relates to a vaccine composition comprising a T- helper cell 2 (Th2) inducing antigen.
In another aspect, the present invention relates to a vaccine composition comprising a Th2 inducing antigen, and an adjuvant, wherein said adjuvant induces T-helper cell 1 (Thl).
In another aspect, the present invention relates to a vaccine as described herein, wherein said adjuvant comprises IL-12.
In another aspect, the present invention relates to a vaccine as described herein, wherein said adjuvant comprises Mycobacterium vaccae, or a part thereof.
In another aspect, the present invention relates to the use of an adjuvant in a vaccine, wherein said adjuvant induces T-helper cell 1 (Thl).
In another aspect, the present invention relates to the use of an adjuvant in a vaccine, wherein said adjuvant comprises IL-12.
In another aspect, the present invention relates to the use of an adjuvant in a vaccine, wherein said adjuvant comprises Mycobacterium vaccae, or a part thereof.
In another aspect, the present invention relates to a method of identifying an antigen for use in a vaccine for mycobacterial disease, said method comprising providing a candidate antigen, providing a first and a second sample of peripheral blood mononuclear cells (PBMCs), contacting said antigen with said first sample of PBMCs, monitoring the expression levels of IL-4 in said first and second samples of PBMCs, and comparing said expression levels of IL-4 in the two samples, wherein antigens inducing raised expression of IL-4 in the first sample of PBMCs as compared to the levels of expression of IL-4 in the second (untreated) sample of PBMCs are identified as useful in said vaccine.
In another aspect, the present invention relates to a method of identifying an antigen for use in a vaccine for mycobacterial disease, said method comprising providing a candidate antigen, providing a first and a second sample of peripheral blood mononuclear cells (PBMCs), contacting said antigen with said first sample of PBMCs, monitoring the expression of CD30 in said first and second samples of PBMCs, and comparing said expression levels of CD30 in the two samples, wherein antigens inducing raised expression of CD30 in the first sample of PBMCs as compared to the
levels of expression of CD30 in the second (untreated) sample of PBMCs are identified as useful in said vaccine.
In another aspect, the present invention relates to a method of identifying an antigen for use in a vaccine for mycobacterial disease as described herein, wherein the mycobacterial agent comprises M.tuberculosis.
In another aspect, the present invention relates to an antigen identified using a method as described herein.
In another aspect, the present invention relates to a vaccine comprising an antigen identified as described herein.
In another aspect, the present invention relates to a pharmaceutical composition comprising an antigen as described herein, and optionally a pharmaceutically acceptable carrier, diluent or excipient.
In another aspect, the present invention relates to a method for immunising a subject comprising administering a vaccine as described herein.
For ease of reference, these and further aspects of the present invention are now discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.
PREFERABLE ASPECTS
Preferably, the adjuvant(s) used in the vaccines of the present invention is capable of inducing Thl . Preferably, said adjuvant may be IL-12.
Preferably, the antigen(s) used in the vaccines of the present invention are capable of inducing a Th2 response.
Preferably, the antigens used in the vaccines of the present invention are capable of inducing IL-4 mRNA and/or IL-4 dependent CD30 expression in normal human mononuclear cells in vitro.
Preferably, the invention relates to vaccine(s) that contain Th2-inducing antigen(s) in Thl-inducing formulation(s).
ADVANTAGES
It is an advantage of the present invention that immunological responses are evoked against Th2-inducing antigens.
It is an advantage of the present invention that antigens may be selected for use in vaccines according to their ability to induce a Th2 response.
TUBERCULOSIS
Tuberculosis is caused by a mycobacterial agent. The term 'mycobacterial agent' as used herein includes the M.tuberculosis bacterium.
In patients with progressive tuberculosis there is not only a Thl lymphocyte response, but as dislcosed herein, there is clear evidence of an inappropriate Th2 response, involving lymphocytes that secrete type 2 cytokines, including interleukin 4 (IL-4) and interleukin 13 (IL-13).
The prior art indicates that this Th2 component is controversial, and its existence is disputed. A further prior art study found that M. tuberculosis caused increased expression of CD30 on human lymphocytes in vitro, but this document (Murik et al, 1997) taught that the increased CD30 expression was attributed to an IL-4-independent pathway.
However, it is surprisingly disclosed herein that the increase in Th2 cytokine expression is significant. Furthermore, our disclosure that the CD30 expression is indeed IL-4-driven is unexpected.
IMMUNOLOGICAL RESPONSE TO MYCOBACTERIAL AGENTS
Both IL-4 and IL-13 mRNAs are expressed at significantly higher levels in fresh unstimulated peripheral blood mononuclear cells from tuberculosis patients (1.4 and 1.2 logs higher respectively) than in cells from matched tuberculin-positive controls. The biological significance of this observation is indicated by significant correlations with radiologic extent of disease, and with a marker of increased type-2 cytokine activity in vivo -- serum IgE (Seah et al, 2000). Previous uncertainty is attributable to methodological difficulties in the prior art, and lack of awareness of an IL-4 splice variant, IL-462. This observation has been confirmed using a flow cytometric technique.
Furthermore, it is shown that there are components of M. tuberculosis that will drive a Th2 component in the in vitro lymphocyte response of peripheral blood mononuclear cells from normal healthy donors. These components are either not present in a control organism, M. vaccae, or present at much lower levels. Clearly, such components are examples of antigens useful in the present invention.
This Th2 component of the response to M. tuberculosis can be measured in vitro in numerous ways, for example by assaying the increase in expression of CD30 on lymphocytes, using flow cytometry, in the presence and in the absence of a neutralising antibody to EL-4. This facilitates the induction of expression of CD30 due to IL-4 to be assessed, without factors other than EL-4 which may contribute to the expression of CD30 adversely affecting the assay.
Another example of a way in which the Th2 component of the response to M. tuberculosis can be measured in vitro in is by assaying expression of IL-4. This can be accomplished for example by extracting RNA from the cultured cells, and performing
a quantitative nested reverse transcription polymerase chain reaction (RT-PCR) for mRNA encoding IL-4. This is preferably done with primers such as those described in Seah and Rook (Seah & Rook, 1999), so that only mRNA encoding IL-4 is measured, and not that encoding IL-462.
These techniques are discussed more fully below, such as in the Examples section.
BIOLOGICAL ROLE OF THE TH2 COMPONENT
Without wishing to be bound by theory, it is believed that the following discussion assists in the illustration of the present invention.
If experimental animals are preimmunised with mycobacterial antigens in such a way that there is a Th2 response present, before challenge with virulent M. tuberculosis, there is accelerated disease and more rapid death than in entirely unimmunised animals (Hernandez-Pando et al, 1997; Lindblad et al, 1997). This may be least partly due to increased toxicity of tumour necrosis factor alpha (TNFa) in mixed Thl/Th2 sites of mycobacterium-induced inflammation (Hernandez-Pando & Rook, 1994).
A similar increase in immunopathology and fibrosis is seen in other models of infection when there is a simultaneous Th2 component. Examples of such are schistosomiasis (Wynn et al, 1995) and Trichinella spiralis (Lawrence et al, 1998).
This is in good agreement with the observation that the extent of Th2 activation in human tuberculosis is directly related to the tissue damage and cavitation (Seah et al, 2000; van Crevel et al, 2000). As well as promoting immunopathology, the increased production of Th2 cytokines such as IL-4 and IL-10 causes decreased macrophage function and impairs bactericidal activity (Powrie et al, 1993).
Thus, when a non-vaccinated subject encounters M. tuberculosis, the lymphocyte response is dominated by Thl cells, but the Th2-inducing components simultaneously induce activation of some Th2 cells. If these become too numerous or active, the Thl
response cannot operate correctly as protective immunity. Therefore, vaccines according to the present invention advantageously inhibit these Th2-inducing components from inducing Th2, and preferably divert, bias or skew the reponse to them into Thl mode.
T HELPER CELLS
The term 'Thl' as used herein refers to a type 1 T-helper cell (Thl). The term may also be used herein to refer to the response mediated by or through such a cell type. Such a response may include one or more of the secretion of Interleukin-2 (IL-2), the secretion of Interferon-gamma (EFN-γ), activation of macrophage, activation of cytotoxic T-cells, or any other Thl -associated event. Thus, the term 'Thl' may include Thl cell(s) as well as the immune response(s) which such cell(s) produce.
The term 'Th2' as used herein refers to a type 2 T-helper cell (Th2). The term may also be used herein to refer to the response mediated by or through such a cell type. Such a response may include one or more of the secretion of Interleukin-4 (EL-4), the secretion of the splice variant interleukin IL-452, the secretion of Interleukin- 13 (IL-13), increase in levels of cell determinant 30 (CD30) on lymphocytes, increase in levels of Immunoglobulin-E (IgE) in the blood, or any other Th2 -associated event. Thus, the term 'Th2' may include Th2 cell(s) as well as the immune response(s) which such cell(s) produce.
VACCINES
The preparation of vaccines which contain one or more substances as an active ingredient(s), is known to one skilled in the art. Typically, such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the active ingredient(s) encapsulated in liposomes. The active ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.
In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents and pH buffering agents.
ADMINISTRATION
Typically, a physician will determine the actual dosage which will be most suitable for an individual subject and it will vary with the age, weight and response of the particular patient. The dosages below are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited.
The compositions of the present invention may be administered by direct injection. The composition may be formulated for parenteral, mucosal, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. Typically, each protein may be administered at a dose of from 0.01 to 30 mg/kg body weight, preferably from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg kg body weight.
The term "administered" includes delivery by delivery mechanisms including injection, lipid mediated transfection, liposomes, immunoliposomes, lipofectin, cationic facial amphiphiles (CFAs) and combinations thereof, or even viral delivery. The routes for
such delivery mechanisms include but are not limited to mucosal, nasal, oral, parenteral, gastrointestinal, topical, or sublingual routes.
The term "administered" includes but is not limited to delivery by a mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestable solution; a parenteral route where delivery is by an injectable form, such as, for example, an intravenous, intramuscular or subcutaneous route.
The term "co-administered" means that the site and time of administration of each of the antigen and/or antigenic determinants of the present invention and an additional entity such as an adjuvant(s) are such that the necessary modulation of the immune system is achieved. Thus, whilst the antigen and adjuvant may be administered at the same moment in time and at the same site, there may be advantages in administering the antigen and/or antigenic determinants at a different time and to a different site from the adjuvant. The antigen and/or antigenic determinants and adjuvant may even be delivered in the same delivery vehicle - and the antigen and/or antigenic determinants and adjuvant(s) may be coupled and/or uncoupled and/or genetically coupled and/or uncoupled.
The antigen, antigenic determinant, peptide or homologue or mimetic thereof may be administered separately or co-administered to the host subject as a single dose or in multiple doses.
The vaccine composition of the invention may be administered by a number of different routes such as injection (which includes parenteral, subcutaneous and intramuscular injection) intranasal, mucosal, oral, intra- vaginal, urethral or ocular administration. Preferably administration is by injection.
For vaccination the vaccine composition can be provided in 0.1 to 0.2 ml of aqueous solution, preferably physiological saline, and administered parenterally, for example by intradermal inoculation. The vaccine according to the invention is preferably injected intracutaneously. Slight swelling and redness, sometimes also itching may be
found at the injection site. The mode of administration, the dose and the number of administrations can be optimised by those skilled in the art in a known manner.
ANTIGENS
As used herein, an "antigen" means an entity which, when introduced into an immunocompetent host, stimulates the production of a specific antibody or antibodies that can combine with the entity, and/or stimulates the relevant Th response, such as Th2. The antigen may be a pure substance, a mixture of substances or soluble or particulate material (including cells or cell fragments or cell sonicate). In this sense, the term includes any suitable antigenic determinant, cross reacting antigen, alloantigen, xenoantigen, tolerogen, allergen, hapten, and immunogen, or parts thereof, as well as any combination thereof, and these terms are used interchangeably throughout the text.
The term "antigenic determinant" as used herein refers to a site on an antigen which is recognised by an antibody or T-cell receptor, or is responsible for evoking the Th2 response. Preferably it is a short peptide derived from or as part of a protein antigen. However the term is also intended to include glycopeptides and carbohydrate epitopes. The term also includes modified sequences of amino acids or carbohydrates which stimulate responses which recognise the whole organism..
It is advantageous if the antigenic determinant is an antigenic determinant of the infectious agent (such as a mycobacterium) which causes the infectious disease.
The present invention provides method(s) for identifying antigen(s) for use in protective and therapeutic vaccines against mycobacterial disease, particularly tuberculosis.
The term "identify" as used in relation to the identification of antigen(s) for use in vaccines according to the present invention, (or for use in the production of such vaccines), is understood to include selecting, validating, confirming, assaying, testing,
assessing or otherwise investigating candidate antigens and thereby determining their suitability for use in vaccine(s) according to the present invention. These techniques are further discussed herein.
A "protective" or "prophylactic" vaccine is a vaccine which is administered to naive individuals to prevent disease development, such as by stimulating active immunity.
A "therapeutic" vaccine is a vaccine which is administered to individuals with an existing infection to reduce or minimise the infection or to abrogate the immunopathological consequences of the disease.
A suitable antigen according to the present invention preferably induces Th2 response(s).
A suitable antigen according to the present invention preferably has one or more of the following properties; capable of inducing IL-4 (interleukin-4) capable of inducing CD30 (cell determinant 30) capable of inducing IL-452 capable of inducing IL- 13 capable of inducing IL-5 capable of inducing IL-10 capable of inducing IL-6 capable of inducing IgE (immunoglobulin E) capable of inducing IgG4 (immunoglobulin gamma 4) capable of inducing other Th-2 associated response(s).
More preferably an antigen according to the present invention has one or more of the following properties; capable of inducing IL-4 (interleukin-4) capable of inducing CD30 (cell determinant 30) capable of inducing IL-452
capable of inducing IL-13 capable of inducing IL-5 capable of inducing IgE (immunoglobulin E) capable of inducing IgG4 (immunoglobulin gamma 4) capable of inducing other Th-2 associated response(s).
More preferably an antigen according to the present invention has one or more of the following properties; capable of inducing IL-4 (interleukin-4) capable of inducing CD30 (cell determinant 30) capable of inducing IgE (immunoglobulin E) capable of inducing IgG4 (immunoglobulin gamma 4) capable of inducing other Th-2 associated response(s).
More preferably an antigen according to the present invention has one or more of the following properties; capable of inducing IL-4 (interleukin-4) capable of inducing CD30 (cell determinant 30) capable of inducing other Th-2 associated response(s).
These properties may be tested according to methods discussed herein, for example by monitoring the effects of candidate antigen(s) on normal human mononuclear cells in vitro.
Thus, the suitability of a candidate antigen may be assessed by measurement of IL-4 mRNA levels in response to contacting normal human mononuclear cells with candidate antigen(s) in vitro. Candidate antigens inducing increased IL-4 mRNA levels are suitable foτ use in vaccines according to the invention.
The suitability of a candidate antigen may be assessed by measurement of CD30 expression in response to contacting normal human mononuclear cells with candidate
antigen(s) in vitro. Candidate antigens inducing increased CD30 levels are suitable for use in vaccines according to the invention.
The suitability of a candidate antigen may be assessed by measurement of IL-4 dependent CD30 expression in response to contacting normal human mononuclear cells with candidate antigen(s) in vitro. This may be accomplished for example by subtracting CD28 mediated CD30 expression produced via CD80, CD86 by using CTLA-4/Fc protein, which inhibits CD28/CD80/CD86 induced expression of CD30, and allows an assessment of the increase in CD30 expression which is attributable to or dependent on IL-4 signalling. As an alternative to using CTLA-4/Fc, neutralising anti-IL-4 antibody may be used to determine the IL-4 induced CD30 expression. Candidate antigens inducing increased IL-4 dependent CD30 levels are suitable for use in vaccines according to the invention.
The suitability of a candidate antigen may be assessed by measurement of IL-10 production in response to contacting normal human mononuclear cells with candidate antigen(s) in vitro. Candidate antigens inducing increased IL-10 levels are suitable for use in vaccines according to the invention.
The suitability of a candidate antigen may be assessed by measurement of IL-13 production in response to contacting normal human mononuclear cells with candidate antigen(s) in vitro. Candidate antigens inducing increased IL-13 levels are suitable for use in vaccines according to the invention.
The suitability of a candidate antigen may be assessed by measurement of IL-462 production in response to contacting normal human mononuclear cells with candidate antigen(s) in vitro. Candidate antigens inducing increased IL-462 levels are suitable for use in vaccines according to the invention.
The suitability of a candidate antigen may be assessed by measurement of IgE production in response to introduction of candidate antigen(s) into an immune system such as by inoculation of a test subject such as a mammalian test subject such as a
mouse. Candidate antigens inducing increased IgE levels are suitable for use in vaccines according to the invention.
The suitability of a candidate antigen may be assessed by measurement of levels of any other suitable Th2 marker in response to candidate antigen(s). Candidate antigens inducing increased Th2 response(s) are suitable for use in vaccines according to the invention.
Preferred antigens according to the present invention are those that induce EL-4 mRNA and/or IL-4 dependent CD30 expression in normal human mononuclear cells in vitro.
M. tuberculosis sonicate (MtbS) serves as an example of an antigen according to the present invention.
ADJUVANTS
The term 'adjuvant' has its normal meaning as used herein, ie. an entity capable of augmenting or participating in the influencing of an immune response. An adjuvant is any substance or mixture of substances that assists, increases, modifies or diversifies the immune response to an antigen. The adjuvant substances may include polypeptides as discussed herein, for example an adjuvant of the present invention may be a polypeptide based molecule or mimetic thereof which itself stimulates an immune response. This is discussed in more detail below. Preferred adjuvants are DL-12, and/or M.vaccae and/or Thl inducing entities.
The vaccine compositions of the present invention may comprise one or a combination of adjuvants which enhance the effectiveness of the vaccine. Examples of additional adjuvants which, may be effective include but are not limited to: aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum), beryllium sulfate, silica, kaolin, carbon, water-in-oil emulsions, oil-in- water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, Corynebacterium parvum (Propionobacterium acnes), Bordetella pertussis, Mycobacterium vaccae, polyribonucleotides, sodium alginate,
lanolin, lysolecithin, vitamin A, interleukins such as interleukin- 12, saponin, liposomes, levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants. Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.) or Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Michigan). Only aluminum hydroxide is approved for human use.
In a preferred aspect, the present invention relates to antigen(s) mixed with a Thl- inducing adjuvant. Examples of such adjuvants include IL-12, M.vaccae, and are discussed herein.
In a preferred aspect, the present invention relates to vaccine that contains one or more Th2-inducing antigen(s) in a Thl-inducing formulation.
Thl-inducing adjuvant could be IL-12, or Mycobacterium vaccae ox part(s) thereof such as sonicate, cell extract, whole cells or analogous material. 'Thl-inducing adjuvant' may comprise one or more other adjuvant(s) with Thl-inducing properties.
Thus, the present invention relates to a Thl-inducing adjuvant.
In a preferred embodiment, the present invention relates to a vaccine that contains Th2 -inducing antigens in a Thl-inducing adjuvant formulation.
Examples of such a vaccine composition include a Th2 inducing antigen mixed with a Thl-inducing adjuvant which adjuvant could be IL-12, or Mycobacterium vaccae ox other adjuvant with Thl-inducing properties.
PHARMACEUTICAL COMPOSITIONS
The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the agent of the present invention (such as vaccine
and or adjuvant compositions) as discussed herein) and a pharmaceutically acceptable carrier, diluent or excipients (including combinations thereof).
The pharmaceutical composition may comprise two components - wherein a first component comprises antigen and a second component which comprises adjuvant thereof. The first and second component may be delivered sequentially, simultaneously or together, and even by different administration routes.
The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine and will typically comprise any one or more of a pharmaceutically acceptable diluent, carrier, or excipient. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).
Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.
There may be different composition/formulation requirements dependent on the different delivery systems. By way of example, the pharmaceutical composition of the present invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestable solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be delivered by both routes. Preferably the formulation is of injectable form.
Where the agent is to be delivered mucosally through the gastrointestinal mucosa, it should be able to remain stable during transit though the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile.
Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. Fox buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
PHARMACEUTICAL COMBINATIONS
The agent of the present invention may be administered with one or more other pharmaceutically active substances. By way of example, the present invention covers the simultaneous, or sequential treatments with an agent according to the present invention and one or more steroids, analgesics, antivirals or other pharmaceutically active substance(s).
It will be understood that these regimes include the administration of the substances sequentially, simultaneously or together.
The present invention will now be described, by way of example only, in which reference will be made to the following figures:
Figure 1, which shows graphs, Figure 2, which shows graphs, Figure 3, which shows a graph, Figure 4, which shows graphs, Figure 5, which shows graphs, and Figure 6, which shows dot plots.
These figures are described in more detail below in the following Example sections.
EXAMPLES
1) M. tuberculosis sonicate drives increased expression of IL-4 mRNA in normal human peripheral blood mononuclear cells in vitro. (Fig 1)
Peripheral blood mononuclear cells were cultured in vitro with ulfrasonically disrupted M. vaccae (MvacS 50 μg/ml) or M. tuberculosis , (MtbS 50 μg/ml) . Control cells were incubated in medium only. On the indicated days replicate wells were harvested and the mRNA was extracted. The copy number of mRNA encoding IL-4 was assayed as described in detail (Seah & Rook, 1999).
Results M. tuberculosis induced significantly more IL-4 mRNA than did M. vaccae and this was biphasic, with peaks at 24 hrs and 7 days.
Figure 1. IL-4 mRNA expression in response to mycobacterial sonicates.
A. IL-4 mRNA expression (by RT-PCR) in NAC cultured for varying time points with M. tuberculosis sonicate (50 μg/ml). This figure represents mean results of duplicate experiments performed with cells of one donor (<5% difference between duplicate results). Since the highest IL-4 mRNA levels were measured at 24 h, this time point was used for the next experiment (shown in B) to compare results from cells of three other donors.
B. IL-4 mRNA expression in NAC harvested after 24 h culture with culture medium alone or with either of the mycobacterial sonicates. MtbS-stimulated cells expressed significantly higher levels of IL-4 mRNA than unstimulated (p=0.0004) or MvacS- stimulated cells (p=0.0005). Statistics by t-test for independent samples. Duplicate experiments were performed using cells for each donor and the results represent the means and 2 SD of data from three different donors. Where error bars are not shown, the error values fall within the symbols.
2) The greater induction of IL-4 mRNA by M. tuberculosis is not secondary to a greater overall proliferative effect (Fig 2).
The lymphoproliferative response evoked in normal human peripheral blood mononuclear cells by MvacS (50 μg/ml), MtbS (50 μg/ml) or culture medium alone, was assessed by H3-thymidine incorporation.
Result
The two mycobacterial sonicate preparations did not differ in their overall stimulation of the cells. Therefore the greater induction of IL-4 mRNA by the MtbS is qualitative difference in its immunological properties.
Figure 2. Lymphocyte proliferation in response to MvacS (50 μg/ml), MtbS (50 μg/ml) or culture medium alone. The difference in proliferative responses to the two mycobacterial sonicates was not significant at any time point (p>0.1 by t-test for
independent samples). The results represent means and 2 SD of data from triplicate wells in one experiment which is representative of three separate experiments showing similar results, performed with cells from different donors . Where error bars are not shown, the error values fall within the symbols.
3) M. tuberculosis sonicate induces expression of CD30 on normal peripheral blood mononuclear cells; time course (Fig 3)
The expression of CD30 on lymphocytes cultured in the presence of MtbS was studied at intervals over a period of nine days. Experiments consistently showed that almost all (>98%) of the CD30+ cells in the lymphogate were T cells (CD3+). CD30 expression peaked at 7 days.
Figure 3. Kinetics of CD30 expression in MtbS-stimulated cultures. NAC were harvested at various time-points for immunostaining and lymphogated cells were analysed by flow cytometry. Mean results and 2 SD of triplicate experiments performed using cells- from one donor are shown, and are representative of three separate experiments performed using cells from different donors. Where error bars are not seen, the error values fall within the symbols.
4) M. tuberculosis sonicate-induced expression of CD30 on normal peripheral blood mononuclear cells; comparison of M. tuberculosis with other stimuli (Fig 4)
The effect of MtbS in inducing CD30 expression was compared with that of MvacS and phytohaemagglutinin (PHA). The effect of PHA was tested, because it was of interest to know whether the CD30 expression was MtbS-specific or merely the result of non-specific T cell activation. PHA-induced CD30 expression in lymphocyte-gated cells rose earlier than that in MtbS-treated cells but peaked at 5% on Day 5, reaching a plateau thereafter. MvacS-treated cells reached similar levels on Day 7, but MtbS- treated cells expressed significantly higher levels of CD30 at the peak on Day 7 (figure 4), with a mean of 12% in four donors, as compared to 5.1% in MvacS-treated cells.
Figure4. CD30 expression in response to different stimulation conditions. PBMCs were cultured in the presence of media alone, phytohaemagglutinin (PHA), MvacS or MtbS as previously described, and CD30 expression on NAC determined at various time-points. Although PHA induced CD30 expression earlier, the highest levels of CD30 expression during the period of observation were induced by MtbS (p<0.002 on Day 7 in comparison to all other antigens). The figure shows means and 2 SD of triplicate assays from one representative experiment out of two performed using cells from different donors.
5) Effect of neutralising antibody to IL-4 on induction of CD30 expression by M. tuberculosis sonicate (Fig 5)
CD30 expression can be induced via CD28 as well as by IL-4. Therefore in order to prove that the CD30 expression seen in cultures containing M. tuberculosis sonicate is at least partly driven by IL-4, experiments were performed in which either 10 μg/ml anti-human IL-4 antibody or an isotype control antibody was included in the culture medium in some wells and their effects on CD30 expression investigated. The optimal concentration of anti-IL-4 was derived by titration (figure 5 A inset). CD30 expression was significantly and consistently reduced by anti-IL4 in MtbS-stimulated lymphocytes of four donors studied in separate experiments (p=0.024 by paired t-test, figure 5 B). Thus, it was deduced that IL-4 significantly influenced CD30 expression on MtbS-stimulated cells..
Figure 5. Effect of inhibiting IL-4 on CD30 expression. PBMCs were cultured in the presence of culture medium alone, MvacS or MtbS as previously described. Either anti-IL4 (10 μg/ml) or isotype control antibody was added to the cultures from Day 0, and CD30 expression on lympho gated cells was determined by flow cytometry. The appropriate concentration of anti-IL4 was determined by titration experiments performed on MtbS-stimulated cells (A inset). A: One representative experiment out of four performed independently using cells from different donors is shown. Assays were performed in triplicate and presented as means and 2 SD. Statistics by t-test for independent samples.
B: Data from the four independent experiments are shown individually, each point representing the mean of triplicate assays based on cells from one donor. The difference in CD30 expression with and without anti-IL4 was significant in MtbS- stimulated lymphocytes (p=0.024) but not in MvacS -stimulated lymphocytes (p=0.16). Statisics by paired t-test (n=4).
6) Comparison of blocking IL-4 and with anti-IL-4, and blocking CD28 with CTLA-4/Fc chimera (Fig 6)
To further demonstrate that at least part of the CD30 expression is driven by IL-4, the relative effects of inhibiting IL-4 activity and CD28 signalling were next considered by peforming further experiments with CTLA-4/Fc chimeric protein. CTLA-4 binds to CD80 and CD86 with 20- 100-fold higher affinity than CD28, thus the chimeric protein acts as a competitive inhibitor of CD28 signalling.
The effect of blocking CD28 signalling was also a significant reduction in CD30 expression (p=0.0004 by paired t-test on data from two independent experiments). However the effect of the anti-IL-4 was of comparable magnitude.
The results are shown in Fig 6 as flow cytometry dot plots.
Figure 6. Effects of IL-4 and CD28 on CD30 expression. Anti-IL4 (10 μg/ml), CTLA- 4/Fc (100 μg/ml) or isotype control antibody were added from Day 0 to PBMCs cultured in the presence of MtbS, and CD30 expression determined on Day 7. The flow cytometry dot plots are gated on lymphocytes and numbers in each quadrant indicate the percentage of gated cells in that quadrant. The diagrams illustrate one
representative assay of triplicates, in one experiment of three performed independently using cells from different donors.
SUMMARY
In summary, the present invention relates to vaccines comprising Th2 inducing antigens as described herein.
The invention further relates to adjuvants comprising Thl inducing entities, and to vaccines comprising same.
The invention also relates to methods for the selection of antigens for use in vaccines as described herein.
All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.
References
Hernandez-Pando R, Pavon L, Arriaga K, Orozco H, Madrid-Marina V and Rook
GAW (1997) Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte. Infect Immun 65:3317-3327.
Hernandez-Pando R and Rook GAW (1994) The role of TNFD in T cell-mediated inflammation depends on the Thl/Th2 cytokine balance. Immunology 82:591-595.
Lawrence CE, Paterson JC, Higgins LM, MacDonald TT, Kennedy MW and Garside P
(1998) IL-4-regulated enteropathy in an intestinal nematode infection. Eur J Immunol 28:2672-2684.
Lindblad EB, Elhay MJ, Silva R, Appelberg R and Andersen P (1997) Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun
65:623-629.
Munk ME, Kern P and Kaufmann SH (1997) Human CD30+ cells are induced by Mycobacterium tuberculosis and present in tuberculosis lesions. Int Immunol 9:713-
20.
Orme I, Flynn JL and Bloom BR (1993) The role of CD8+ T cells in immunity to tuberculosis. Trends Microbiol 1:77-78.
Orme IM, Andersen P and Boom WH (1993) T cell response to Mycobacterium tuberculosis. J Infect Dis 167:1481-1497.
Powrie F, Menon S and Coffman RL (1993) Interleukin-4 and interleukin- 10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 23:3043-9.
Seah GT and Rook GA (1999) A sensitive, non-radioactive quantitative method for measuring IL-4 and IL-4delta2 mRNA in unstimulated cells from multiple clinical samples, using nested RT-PCR. J Immunol Methods 228: 139-149.
Seah GT, Scott GM and Rook GA (2000) Type 2 Cytokine Gene Activation and Its
Relationship to Extent of Disease in Patients with Tuberculosis. J Infect Dis 181:385-
389.
Silver RF, Li Q, Boom WH and Elmer JJ (1998) Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. J Immunol 160:2408-17.
Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, S. T- U, Melian A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM and Modlin RL (1998) An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282:121-125. van Crevel R, Karyadi E, Preyers F, Leenders M, KuUberg BJ, Nelwan RH and van Der Meer J (2000) Increased Production of Interleukin 4 by CD4+ and CD8+ T Cells from Patients with Tuberculosis Is Related to the Presence of Pulmonary Cavities. J Infect Dis 181:1194-1197.
Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P, Lewis FA and Sher A (1995) An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 376:594-596.
Claims (15)
1. A vaccine composition comprising an antigen capable of inducing a T-helper cell 2 (Th2).
2. A vaccine composition comprising an antigen capable of inducing a Th2, and an adjuvant, wherein said adjuvant induces T-helper cell 1 (Thl).
3. Use of an adjuvant in a vaccine wherein said adjuvant is capable of inducing T- helper cell 1 (Thl).
4. Use of an adjuvant in a vaccine wherein said adjuvant is capable of inducing T- helper cell 1 (Thl); and wherein said adjuvant comprises IL-12.
5. Use of an adjuvant in a vaccine wherein said adjuvant is capable of inducing T- helper cell 1 (Thl); and wherein said adjuvant comprises Mycobacterium vaccae, or a part thereof.
6. A vaccine according to claim 2 wherein said adjuvant comprises IL-12.
7. A vaccine according to claim 2 wherein said adjuvant comprises Mycobacterium vaccae, or a part thereof.
8. A method of identifying an antigen for use in a vaccine for mycobacterial disease, said method comprising
(i) providing a candidate antigen;
(ii) providing a first and a second sample of peripheral blood mononuclear cells (PBMCs);
(iii) contacting said antigen with said first sample of PBMCs; (iv) monitoring the expression levels of IL-4 in said first and second samples of PBMCs; and (v) comparing the expression levels of IL-4 of step (iv), wherein antigens inducing raised expression of IL-4 in the first sample of PBMCs as compared to the levels of expression of IL-4 in the second (untreated) sample of PBMCs are identified as useful in said vaccine.
9. A method of identifying an antigen for use in a vaccine for mycobacterial disease, said method comprising
(i) providing a candidate antigen;
(ii) providing a first and a second sample of peripheral blood mononuclear cells
(PBMCs); (iii) contacting said antigen with said first sample of PBMCs;
(iv) monitoring the expression of CD30 in said first and second samples of PBMCs; and
(v) comparing the expression levels of CD30 of step (iv), wherein antigens inducing raised expression of CD30 in the first sample of PBMCs as compared to the levels of expression of CD30 in the second (untreated) sample of
PBMCs are identified as useful in said vaccine.
10. A method according to claim 9 wherein the expression levels of CD30 are IL-4 mediated expression levels.
11. A method according to any of claims 8 to 10 wherein the mycobacterial disease agent comprises M.tuberculosis.
12. An antigen identified by a method according to any of claims 8 to 11.
13. A vaccine comprising an antigen according to claim 12.
14. A pharmaceutical composition comprising an antigen as defined in any one of the preceding claims, and optionally a pharmaceutically acceptable carrier, diluent or excipient.
15. A method for immunising a subject comprising administering to a subject in need of same a vaccine according to any preceding claim.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0025694.1A GB0025694D0 (en) | 2000-10-19 | 2000-10-19 | Vaccine |
GB0025694.1 | 2000-10-19 | ||
PCT/GB2001/004572 WO2002032455A2 (en) | 2000-10-19 | 2001-10-15 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001295721A1 true AU2001295721A1 (en) | 2002-04-29 |
Family
ID=9901650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001295721A Abandoned AU2001295721A1 (en) | 2000-10-19 | 2001-10-15 | Vaccine |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040037844A1 (en) |
EP (1) | EP1363665A2 (en) |
AU (1) | AU2001295721A1 (en) |
GB (1) | GB0025694D0 (en) |
WO (1) | WO2002032455A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2471241T3 (en) | 2002-09-06 | 2014-06-25 | Ucl Business Plc | Complete bacterial cells as an immunomodulator |
US7442374B2 (en) | 2004-07-19 | 2008-10-28 | Ucl Biomedica Plc | Composition for increasing the survival to slaughter rate of piglets |
GB0526033D0 (en) | 2005-12-21 | 2006-02-01 | Bioeos Ltd | Method |
GB0716778D0 (en) | 2007-08-29 | 2007-10-10 | Bioeos Ltd | Use |
WO2019165217A1 (en) * | 2018-02-22 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd153 and/or cd30 in infection |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69126668T2 (en) * | 1990-11-08 | 1997-10-23 | Univ London | MYCOBACTERIUM AS ADJUVANS FOR ANTIGENS |
US5571515A (en) * | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
CA2232501A1 (en) * | 1995-09-18 | 1997-03-27 | The Board Of Trustees Of The University Of Illinois | An immunostimulant and antineoplastic glycan obtained from mycobacterium vaccae |
US6878377B2 (en) * | 1996-12-18 | 2005-04-12 | Stanford Rook Limited | Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system |
WO2002054072A2 (en) * | 2001-01-08 | 2002-07-11 | Isis Innovation Limited | Assay to determine efficacy of treatment for mycobacterial infection |
-
2000
- 2000-10-19 GB GBGB0025694.1A patent/GB0025694D0/en not_active Ceased
-
2001
- 2001-10-15 AU AU2001295721A patent/AU2001295721A1/en not_active Abandoned
- 2001-10-15 EP EP01976451A patent/EP1363665A2/en not_active Withdrawn
- 2001-10-15 US US10/399,565 patent/US20040037844A1/en not_active Abandoned
- 2001-10-15 WO PCT/GB2001/004572 patent/WO2002032455A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1363665A2 (en) | 2003-11-26 |
GB0025694D0 (en) | 2000-12-06 |
WO2002032455A2 (en) | 2002-04-25 |
US20040037844A1 (en) | 2004-02-26 |
WO2002032455A3 (en) | 2003-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100399258B1 (en) | Effective Enterotoxin Mutations as Nontoxic Oral Terminology | |
Hunter et al. | Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha | |
Brown et al. | Immune control of Babesia bovis infection | |
US9085616B2 (en) | Toll-like receptor 5 ligands and methods of use | |
Miller et al. | Nonviable bacterial antigens administered with IL-12 generate antigen-specific T cell responses and protective immunity against Listeria monocytogenes. | |
JP5165681B2 (en) | Expansion of T cell repertoire containing subdominant epitopes by vaccination with antigen delivered as protein fragments or peptide cocktails | |
US6410720B1 (en) | Compounds and methods for treatment and diagnosis of mycobacterial infections | |
Ulmer et al. | Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination | |
Michetti et al. | Gastric mucosal α4β7-integrin—positive CD4 T lymphocytes and immune protection against Helicobacter infection in mice | |
AU746311B2 (en) | Compositions derived from (mycobacterium vaccae) and methods for their use | |
US20120003267A1 (en) | Therapeutic Agents | |
EP1684803B1 (en) | Immune modulator comprising whole cell tsukamurella bacteria | |
US20040037844A1 (en) | Vaccine | |
KR20070067719A (en) | Immunomodulators for vaccines | |
US5599541A (en) | Peptide sequence capable of inducing a delayed-type hypersensitivity reaction in the presence of living bacteria of the Mycobacterium tuberculosis complex and its applications | |
Tvede et al. | Interleukin 2 receptor expression by human blood lymphocytes after vaccination with pneumococcal polysaccharides. | |
US6406704B1 (en) | Compounds and methods for treatment and diagnosis of mycobacterial infections | |
EP0876156A1 (en) | Compositions and methods for administering borrelia burgdorferi antigens | |
US7914791B1 (en) | Vaccine | |
KR20010033132A (en) | Compositions derived from mycobacterium vaccae and methods for their use | |
Rebelatto | Nasal-associated lymphoid tissue and intranasal immunizations in cattle | |
Elhofy | Regulation of the early immune response by Salmonella | |
IMMUNOSTIMULATING et al. | REGULATORY MOLECULE | |
CA2243526A1 (en) | Compositions and methods for administering borrelia burgdorferi antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |